Methylene Blue Partially Rescues Heart Defects in a Drosophila Model of Huntington's Disease [0.03%]
美蓝部分修复了亨廷顿舞蹈病果蝇模型中的心脏缺陷
Raheleh Heidari,Véronique Monnier,Elodie Martin et al.
Raheleh Heidari et al.
Background: Huntington's disease (HD) is a Polyglutamine disease caused by the presence of CAG repeats in the first exon of Huntingtin (Htt), a large protein with multiple functions. In addition to neurodegeneration of sp...
Matthew Mort,Francesca A Carlisle,Adrian J Waite et al.
Matthew Mort et al.
Background: A CAG repeat expansion in HTT has been known to cause Huntington's disease for over 20 years. The genomic sequence of the 67 exon HTT is clear but few reports have detailed alternative splicing or alternative ...
In Vivo MRI Evidence that Neuropathology is Attenuated by Cognitive Enrichment in the Yac128 Huntington's Disease Mouse Model [0.03%]
Yac128亨廷顿舞蹈病小鼠模型中认知增强可减轻神经病理损害的体内MRI证据
Jessica J Steventon,David J Harrison,Rebecca C Trueman et al.
Jessica J Steventon et al.
Background: Environmental enrichment has been shown to improve symptoms and reduce neuropathology in mouse models of Huntington's disease (HD); however results are limited to ex vivo techniques with associated shortcoming...
Is There Convincing Evidence that Intermediate Repeats in the HTT Gene Cause Huntington's Disease? [0.03%]
HTT基因中介重复引起的亨廷顿舞蹈病的证据充分吗？
Mayke Oosterloo,Martine J Van Belzen,Emilia K Bijlsma et al.
Mayke Oosterloo et al.
Background and objective: Huntington's disease (HD) is a neurodegenerative disease associated with a CAG repeat expansion in the Huntingtin (HTT) gene. A trinucleotide size between 27 and 35 is considered 'intermediate' a...
Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease [0.03%]
抗多巴胺药物与进展更快的亨廷顿舞蹈病相关
Joakim Tedroff,Susanna Waters,Roger A Barker et al.
Joakim Tedroff et al.
Background: Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder leading to progressive motor, cognitive and functional decline. Antidopaminergic medications (ADMs) are frequently used to treat ch...
Dual Task Performance May be a Better Measure of Cognitive Processing in Huntington's Disease than Traditional Attention Tests [0.03%]
亨廷顿舞蹈病的认知处理以双任务表现测量可能比传统注意力测试更为有效的测量方式
Eleftheria Vaportzis,Nellie Georgiou-Karistianis,Andrew Churchyard et al.
Eleftheria Vaportzis et al.
Background: Past research has found cancellation tasks to be reliable markers of cognitive decline in Huntington's disease (HD). Objective: ...
Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's Disease [0.03%]
色氨酸2，3双氧化酶作为亨廷顿舞蹈病的治疗靶点的潜力研究
Gelareh Mazarei,Blair R Leavitt
Gelareh Mazarei
Within the past decade, there has been increasing interest in the role of tryptophan (Trp) metabolites and the kynurenine pathway (KP) in diseases of the brain such as Huntington's disease (HD). Evidence is accumulating to suggest that this...
Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease [0.03%]
醋酸格拉默在亨廷顿舞蹈病中修正疾病进程的潜能
Jody Corey-Bloom,Haiqun Jia,Alaina M Aikin et al.
Jody Corey-Bloom et al.
Background: Deficiencies in brain-derived-neurotrophic-factor have been implicated in the pathogenesis of Huntington's disease (HD). Objective: ...
'Super-Enrichment' Reveals Dose-Dependent Therapeutic Effects of Environmental Stimulation in a Transgenic Mouse Model of Huntington's Disease [0.03%]
“超级富集”揭示了环境刺激在亨廷顿舞蹈病转基因小鼠模型中的剂量依赖性治疗效应
Nektarios K Mazarakis,Christina Mo,Thibault Renoir et al.
Nektarios K Mazarakis et al.
Background: Huntington's disease (HD) is caused by a tandem repeat expansion and involves progressive cognitive decline, psychiatric abnormalities and motor deficits. Disease onset and progression in HD mice can be substa...
Co-administration of the Dopaminergic Stabilizer Pridopidine and Tetrabenazine in Rats [0.03%]
帕金森模型小鼠中多巴胺稳定剂普拉西汀与四苯喹嗪联合给药研究
Susanna Waters,Henrik Ponten,Daniel Klamer et al.
Susanna Waters et al.
Background: The efficacy of the dopaminergic stabilizer, pridopidine, in reducing the voluntary and involuntary motor symptoms of Huntington's disease (HD) is under clinical evaluation. Tetrabenazine is currently the only...